Balyasny Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.26M | Sell |
252,414
-333,792
| -57% | -$2.99M | ﹤0.01% | 1132 |
|
|
2025
Q1 | $4.4M | Buy |
586,206
+56,553
| +11% | +$424K | 0.01% | 892 |
|
|
2024
Q4 | $3.98M | Buy |
+529,653
| New | +$3.98M | 0.01% | 918 |
|
|
2024
Q1 | – | Sell |
-1,971,586
| Closed | -$11.8M | – | 1988 |
|
|
2023
Q4 | $11.8M | Buy |
1,971,586
+1,563,289
| +383% | +$9.36M | 0.02% | 589 |
|
|
2023
Q3 | $2.89M | Buy |
+408,297
| New | +$2.89M | 0.01% | 915 |
|
|
2022
Q4 | – | Sell |
-1,223,721
| Closed | -$15.4M | – | 2327 |
|
|
2022
Q3 | $15.4M | Buy |
1,223,721
+29,210
| +2% | +$368K | 0.05% | 425 |
|
|
2022
Q2 | $12.6M | Buy |
+1,194,511
| New | +$12.6M | 0.04% | 472 |
|
|
2020
Q2 | – | Sell |
-3,005,676
| Closed | -$6.01M | – | 961 |
|
|
2020
Q1 | $6.01M | Buy |
+3,005,676
| New | +$6.01M | 0.07% | 322 |
|
|
2018
Q1 | – | Sell |
-11,091
| Closed | -$54K | – | 1744 |
|
|
2017
Q4 | $54K | Sell |
11,091
-42,705
| -79% | -$208K | ﹤0.01% | 1760 |
|
|
2017
Q3 | $282K | Buy |
+53,796
| New | +$282K | ﹤0.01% | 1358 |
|
|
2015
Q3 | – | Sell |
-87,111
| Closed | -$1.3M | – | 974 |
|
|
2015
Q2 | $1.3M | Buy |
+87,111
| New | +$1.3M | 0.01% | 559 |
|